Wee1 kinase as a target for cancer therapy
Cell Cycle2013Vol. 12(19), pp. 3348–3353
Citations Over TimeTop 10% of 2013 papers
Abstract
Wee1, a protein kinase, regulates the G 2 checkpoint in response to DNA damage. Preclinical studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer. MK-1775, a selective and potent small-molecule inhibitor of wee1, is under clinical development as a potentiator of DNA damage caused by cytotoxic chemotherapies. We present a review of the role of wee1 in the cell cycle and DNA replication and summarize the clinical development to date of this novel class of anticancer agents.
Related Papers
- → Knockdown of Chk1, Wee1 and Myt1 by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis(2004)134 cited
- → Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition(2012)82 cited
- → Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation(2011)76 cited
- → HIV-1 Vpr induces G2 cell cycle arrest in fission yeast associated with Rad24/14-3-3-dependent, Chk1/Cds1-independent Wee1 upregulation(2006)20 cited
- → Antagonism of Chk1 Signaling in the G2 DNA Damage Checkpoint by Dominant Alleles of Cdr1(2006)12 cited